{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:55:52Z","timestamp":1787788552882,"version":"build-2784847793"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Migraine is a neurological condition marked by frequent headaches, which tends to be accompanied by nausea and vomiting in severe instances. Injectable therapies for migraine, such as monoclonal antibodies that target calcitonin gene-related peptide (CGRP), have proven to be effective and safe. While various oral drugs are available, none have been developed for migraines. Patients prefer oral therapies because they are easier to use, making atogepant, an orally accessible small-molecule CGRP receptor antagonist, a possible alternative.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This systematic review and meta-analysis compared the safety and effectiveness of atogepant with placebo in treating migraine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adhering to the PRISMA guidelines, we meticulously gathered randomized controlled trials (RCTs) from databases including the Cochrane Library, PubMed, Science Direct, and <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>. Studies comparing atogepant with placebo and reporting monthly migraine days (MMDs) as the primary outcome along with secondary outcomes such as monthly headache days and acute medication use days were included. Two independent reviewers conducted the data extraction and quality assessment. Statistical analyses were carried out using RevMan, utilizing risk ratios for dichotomous outcomes and mean differences for continuous outcomes, and a random-effects model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our primary outcome was the change in MMDs over 12\u2009weeks, which showed a significant reduction with atogepant at dosages of 10, 30, and 60\u2009mg. Secondary outcomes, such as monthly headache days, proportion of patients achieving a\u2009\u2265\u200950% reduction in MMDs, acute medication use days, and patient-reported outcomes, consistently showed that atogepant outperformed placebo, highlighting its effectiveness in reducing the migraine burden.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Higher doses of atogepant are more effective in lowering migraine and headache-related days and increasing quality of life metrics. However, this is accompanied by an increased incidence of adverse events, suggesting the need for careful dose optimization to balance the benefits and risks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?RecordID=563395<\/jats:ext-link>. Unique Identifier: CRD42024563395.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1468961","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T04:41:36Z","timestamp":1727412096000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults"],"prefix":"10.3389","volume":"15","author":[{"given":"Adarsh","family":"Raja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Asim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hamza","family":"Shuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandesh","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tazheen Saleh","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Hadi","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iffat Ambreen","family":"Magsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hammad","family":"Faridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza Ali Hasnain","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Junaid","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Sohaib","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01402-2","article-title":"The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates","volume":"23","author":"Stovner","year":"2022","journal-title":"J Headache Pain"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1111\/head.13966","article-title":"Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American migraine prevalence and prevention (AMPP) study","volume":"60","author":"Buse","year":"2020","journal-title":"Headache"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","volume":"28","author":"Goadsby","year":"1990","journal-title":"Ann Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards Subcommittee of the American Academy of neurology and the American headache society","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurol Int"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)","volume":"53","author":"Blumenfeld","year":"2013","journal-title":"Headache"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/17460441.2024.2365379","article-title":"The preclinical discovery and development of atogepant for migraine prophylaxis","volume":"19","author":"Baraldi","year":"2024","journal-title":"Expert Opin Drug Discov"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.S17.001","article-title":"Orally administered Atogepant was efficacious, safe, and tolerable for the prevention of migraine: results from a phase 2b\/3 study (S17.001)","volume":"92","author":"Goadsby","year":"2019","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","article-title":"Systematic review of migraine prophylaxis adherence and persistence","volume":"20","author":"Hepp","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/03331024211042385","article-title":"Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial","volume":"42","author":"Schwedt","year":"2022","journal-title":"Cephalalgia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/14656566.2024.2349791","article-title":"Pharmacological management of migraine: current strategies and future directions","volume":"25","author":"Pellesi","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","article-title":"Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Pozo-Rosich","year":"2023","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1212\/WNL.0000000000209584","article-title":"Efficacy of Atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial","volume":"103","author":"Goadsby","year":"2024","journal-title":"Neurol Int"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(24)00025-5","article-title":"Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial","volume":"23","author":"Tassorelli","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"Ailani","year":"2021","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40120-022-00370-8","article-title":"Atogepant for the prevention of episodic migraine in adults: a systematic review and Meta-analysis of efficacy and safety","volume":"11","author":"Lattanzi","year":"2022","journal-title":"Neurol Ther"},{"key":"ref20","unstructured":""},{"key":"ref21","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","article-title":"EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force","volume":"16","author":"Evers","year":"2009","journal-title":"Eur J Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.1021\/acs.jmedchem.9b01810","article-title":"Blocking the CGRP pathway for acute and preventive treatment of migraine: the evolution of success","volume":"63","author":"Dubowchik","year":"2020","journal-title":"J Med Chem"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/head.14439","article-title":"Once-daily oral atogepant for the long-term preventive treatment of migraine: findings from a multicenter, randomized, open-label, phase 3 trial","volume":"63","author":"Ashina","year":"2023","journal-title":"Headache"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","article-title":"Migraine: epidemiology and systems of care","volume":"397","author":"Ashina","year":"2021","journal-title":"Lancet"},{"key":"ref25","volume-title":"Final draft guidance Atogepant for preventing migraine 1 Recommendations","year":"2024"}],"updated-by":[{"DOI":"10.3389\/fneur.2025.1577914","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000}}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1468961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:15:42Z","timestamp":1744355742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1468961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":25,"alternative-id":["10.3389\/fneur.2024.1468961"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1468961","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fneur.2025.1577914","asserted-by":"object"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"article-number":"1468961"}}